Published in J Natl Cancer Inst on August 04, 1999
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer (2009) 3.99
Histopathological identification of colon cancer with microsatellite instability. Am J Pathol (2001) 2.90
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res (2008) 2.32
Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res (2010) 2.18
Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol (2001) 2.13
Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut (2001) 2.08
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology (2009) 2.04
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut (2005) 1.87
Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol (2009) 1.84
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist (2010) 1.72
Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci U S A (2000) 1.55
DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer (2010) 1.55
Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer (2005) 1.47
Genetic alterations in colorectal cancer. Gastrointest Cancer Res (2012) 1.44
Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet (2002) 1.41
Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol (2012) 1.37
Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis (2006) 1.32
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol (2011) 1.31
Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One (2012) 1.30
KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol (2009) 1.26
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist (2010) 1.26
Microsatellite instability and survival in rectal cancer. Cancer Causes Control (2009) 1.24
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer (2009) 1.18
Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn (2008) 1.17
Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol (2009) 1.14
Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. Gastroenterology (2012) 1.09
Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res (2008) 1.08
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis (2003) 1.07
DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol (2010) 1.07
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int J Colorectal Dis (2006) 1.06
Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br J Cancer (2001) 1.04
Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer (2011) 1.04
Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma. Gut (2005) 1.02
Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer (2002) 1.00
Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol (2011) 0.98
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer (2010) 0.98
Death from early colorectal cancer is predicted by the presence of transcripts of the REG gene family. Br J Cancer (2000) 0.98
Microsatellite instability testing in Korean patients with colorectal cancer. Fam Cancer (2012) 0.97
Prognostic significance of microsatellite instability in sporadic colorectal cancer. Int J Colorectal Dis (2004) 0.96
Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol (2015) 0.96
Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer. World J Gastroenterol (2007) 0.96
Prognosis in DNA mismatch repair deficient colorectal cancer: are all MSI tumours equivalent? Fam Cancer (2004) 0.96
Current status of adjuvant therapy for colon cancer. Gastrointest Cancer Res (2007) 0.95
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw (2011) 0.95
Chromosomal aberrations related to metastasis of human solid tumors. World J Gastroenterol (2002) 0.95
Prognostic and predictive significance of MSI in stages II/III colon cancer. World J Gastroenterol (2014) 0.95
SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol (2011) 0.95
The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis (2006) 0.94
Chromosomal instability in BRAF mutant, microsatellite stable colorectal cancers. PLoS One (2012) 0.93
Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn (2010) 0.93
The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol (2006) 0.92
Allelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis. J Cancer Res Clin Oncol (2003) 0.91
Genome characteristics of primary carcinomas, local recurrences, carcinomatoses, and liver metastases from colorectal cancer patients. Mol Cancer (2004) 0.91
Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy. Gastrointest Cancer Res (2009) 0.91
A meta-analysis of MSI frequency and race in colorectal cancer. Oncotarget (2016) 0.90
Prognostic biomarkers in colorectal cancer: where do we stand? Virchows Arch (2014) 0.87
Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Surg Today (2012) 0.87
Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer. Br J Cancer (2013) 0.85
From the genome to the proteome--biomarkers in colorectal cancer. Langenbecks Arch Surg (2007) 0.84
Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study. World J Surg Oncol (2010) 0.84
Relationships of tumor inflammatory infiltration and necrosis with microsatellite instability in colorectal cancers. World J Gastroenterol (2005) 0.83
Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients. Int J Mol Sci (2017) 0.83
Prognostic factors in node-negative colorectal cancer: a retrospective study from a prospective database. Int J Colorectal Dis (2010) 0.81
Analysis of allelic imbalance in patients with colorectal cancer according to stage and presence of synchronous liver metastases. Ann Surg (2001) 0.81
Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J Gastrointest Oncol (2015) 0.81
A microRNA molecular modeling extension for prediction of colorectal cancer treatment. BMC Cancer (2015) 0.80
Inherited colorectal cancer syndromes. Clin Colon Rectal Surg (2009) 0.79
Sporadic colorectal carcinomas with low-level microsatellite instability: a distinct subgroup with specific clinicopathological and molecular features. Int J Colorectal Dis (2011) 0.79
Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance. Oncotarget (2015) 0.79
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer. Br J Cancer (2005) 0.79
Allelic imbalance of 8p indicates poor survival in gastric cancer. J Mol Diagn (2004) 0.78
Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer. World J Gastroenterol (2007) 0.78
Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Future Oncol (2011) 0.78
Copy number alterations and allelic ratio in relation to recurrence of rectal cancer. BMC Genomics (2015) 0.77
Prognostic value of colorectal cancer biomarkers. Cancers (Basel) (2011) 0.77
Microsatellite instability in colorectal cancer: prognostic, predictive or both? Am J Pathol (2002) 0.75
1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer. BMC Cancer (2014) 0.75
Prognostic values of chromosome 18q microsatellite alterations in stage II colonic carcinoma. World J Gastroenterol (2010) 0.75
Association between hMLH1 hypermethylation and JC virus (JCV) infection in human colorectal cancer (CRC). Clin Epigenetics (2010) 0.75
A novel multiplexing, polymerase chain reaction-based assay for the analysis of chromosome 18q status in colorectal cancer. J Mol Diagn (2005) 0.75
Molecular markers of prognosis in colorectal cancer. J Natl Cancer Inst (1999) 0.75
[Clinical, pathological and molecular prognostic factors in colorectal carcinomas]. Pathologe (2003) 0.75
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med (1996) 10.60
Interstitial Myocarditis Following the Clinical and Experimental Use of Sulfonamide Drugs. Am J Pathol (1942) 10.27
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med (1999) 7.81
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med (2001) 7.59
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 5.68
Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell (2001) 5.19
Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered (2003) 5.06
Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res (1998) 4.39
Evaluation of candidate genes in case-control studies: a statistical method to account for related subjects. Am J Hum Genet (2001) 4.09
Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA (1993) 3.91
Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA (1995) 3.84
Ultralong single-wall carbon nanotubes. Nat Mater (2004) 3.83
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol (1989) 3.44
Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst (2001) 3.37
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med (1985) 3.36
Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res (1998) 3.36
Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet (2000) 3.33
Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science (1998) 3.22
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J (1999) 3.18
Incidence of reading disability in a population-based birth cohort, 1976-1982, Rochester, Minn. Mayo Clin Proc (2001) 3.18
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood (1993) 2.98
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer (1991) 2.98
Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res (1996) 2.89
Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer (1982) 2.85
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet (2004) 2.75
Phytochelatin synthase genes from Arabidopsis and the yeast Schizosaccharomyces pombe. Plant Cell (1999) 2.74
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med (1986) 2.70
The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet (2001) 2.68
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med (1997) 2.66
Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med (1979) 2.63
Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology (1999) 2.62
Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology (1999) 2.56
Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol (2001) 2.54
Brunner's gland hamartomas: clinical presentation and pathological features of 27 cases. Am J Gastroenterol (1995) 2.52
Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol (1998) 2.48
Incidence of high blood lead levels in Chicago children. Pediatrics (1969) 2.46
Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med (2001) 2.41
Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res (2000) 2.38
Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med (1997) 2.38
Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology (2000) 2.31
Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology (2001) 2.30
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (2003) 2.28
Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology (1998) 2.26
Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology (2000) 2.25
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med (1997) 2.25
Incremental costs of enrolling cancer patients in clinical trials: a population-based study. J Natl Cancer Inst (1999) 2.25
Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation. Gut (2002) 2.24
Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol (1998) 2.24
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord (2000) 2.20
Potential influence of migration bias in birth cohort studies. Mayo Clin Proc (1998) 2.19
Case-control studies of genetic markers: power and sample size approximations for Armitage's test for trend. Hum Hered (2001) 2.14
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol (2001) 2.10
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med (2001) 2.09
Hypersensitivity in the Pathogenesis of the Histopathologic Changes Associated with Sulfonamide Chemotherapy. Am J Pathol (1946) 2.08
Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr (1998) 2.05
Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut (2001) 2.05
GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell (1998) 2.03
Thalidomide as initial therapy for early-stage myeloma. Leukemia (2003) 2.02
Brain metastases from colorectal carcinoma. The long term survivors. Cancer (1996) 2.01
Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol (2001) 2.00
Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acids Res (1998) 1.99
Rad18 is required for DNA repair and checkpoint responses in fission yeast. Mol Biol Cell (1999) 1.98
Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med (1998) 1.96
Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer (2000) 1.95
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol (1991) 1.93
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol (1994) 1.93
Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol (2001) 1.93
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst (1990) 1.92
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia (2011) 1.92
Sequence analysis of the fragile X trinucleotide repeat: implications for the origin of the fragile X mutation. Hum Mol Genet (1994) 1.90